TP53 and cancer: Furthermore, the contrasting apoptotic responses between AT treatment and the chemotherapeutic agent mitomycin C’s dependence on p53–Bak-associated pathways underscore the differential activation of intrinsic apoptosis pathways across cancer cell lines.